Revvity, Inc.

NYSE:RVTY Stock Report

Market Cap: US$15.6b

Revvity Valuation

Is RVTY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RVTY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: RVTY ($145.73) is trading above our estimate of future cash flow value ($134.64)

Significantly Below Future Cash Flow Value: RVTY is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RVTY?

Key metric: As RVTY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RVTY. This is calculated by dividing RVTY's market cap by their current earnings.
What is RVTY's PE Ratio?
PE Ratio68.5x
EarningsUS$237.37m
Market CapUS$15.64b

Price to Earnings Ratio vs Peers

How does RVTY's PE Ratio compare to its peers?

The above table shows the PE ratio for RVTY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average41.2x
TECH Bio-Techne
62.4x14.37%US$11.3b
BIO Bio-Rad Laboratories
45.6x0.14%US$10.0b
QGEN Qiagen
21.7x10.96%US$8.8b
MEDP Medpace Holdings
35x8.36%US$17.3b
RVTY Revvity
68.5x22.69%US$15.6b

Price-To-Earnings vs Peers: RVTY is expensive based on its Price-To-Earnings Ratio (68.5x) compared to the peer average (41.2x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does RVTY's PE Ratio compare vs other companies in the US Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
RVTY 68.5xIndustry Avg. 36.5xNo. of Companies5PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: RVTY is expensive based on its Price-To-Earnings Ratio (68.5x) compared to the Global Life Sciences industry average (36.5x).

Price to Earnings Ratio vs Fair Ratio

What is RVTY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RVTY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio68.5x
Fair PE Ratio27.1x

Price-To-Earnings vs Fair Ratio: RVTY is expensive based on its Price-To-Earnings Ratio (68.5x) compared to the estimated Fair Price-To-Earnings Ratio (27.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RVTY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$145.73
US$126.12
-13.46%
12.75%US$165.00US$100.00n/a17
Sep ’27US$126.59
US$121.94
-3.68%
9.43%US$145.00US$100.00n/a16
Aug ’27US$112.52
US$117.13
+4.10%
12.75%US$145.00US$90.00n/a15
Jul ’27US$112.84
US$113.73
+0.79%
12.17%US$145.00US$90.00n/a15
Jun ’27US$100.52
US$113.64
+13.05%
12.60%US$145.00US$90.00n/a14
May ’27US$86.68
US$113.93
+31.44%
12.28%US$140.00US$95.00n/a14
Apr ’27US$87.92
US$118.93
+35.27%
9.92%US$140.00US$96.00n/a15
Mar ’27US$98.31
US$119.56
+21.62%
8.75%US$140.00US$105.00n/a16
Feb ’27US$108.80
US$116.19
+6.79%
9.23%US$140.00US$100.00n/a16
Jan ’27US$96.75
US$114.38
+18.22%
8.09%US$135.00US$100.00n/a16
Dec ’26US$102.43
US$113.67
+10.97%
8.88%US$135.00US$100.00n/a15
Nov ’26US$93.59
US$113.67
+21.45%
8.88%US$135.00US$100.00n/a15
Oct ’26US$91.76
US$115.81
+26.21%
13.40%US$162.00US$99.00n/a16
Sep ’26US$90.11
US$116.81
+29.63%
12.76%US$162.00US$100.00US$126.5916
Aug ’26US$88.23
US$116.81
+32.40%
12.76%US$162.00US$100.00US$112.5216
Jul ’26US$99.03
US$124.18
+25.40%
15.19%US$169.11US$100.00US$112.8417
Jun ’26US$90.42
US$124.84
+38.07%
14.62%US$169.11US$100.00US$100.5218
May ’26US$92.90
US$124.44
+33.95%
13.92%US$162.00US$100.00US$86.6818
Apr ’26US$104.31
US$141.10
+35.27%
7.96%US$162.00US$120.00US$87.9218
Mar ’26US$112.15
US$141.19
+25.89%
8.07%US$163.44US$120.00US$98.3118
Feb ’26US$126.13
US$139.64
+10.71%
8.40%US$163.44US$120.00US$108.8018
Jan ’26US$111.61
US$138.47
+24.06%
8.64%US$163.44US$120.00US$96.7518
Dec ’25US$116.14
US$138.68
+19.40%
8.25%US$162.17US$120.00US$102.4318
Nov ’25US$121.04
US$137.90
+13.93%
8.44%US$162.17US$120.00US$93.5918
Oct ’25US$124.44
US$133.87
+7.58%
7.76%US$162.00US$120.00US$91.7618
Sep ’25US$122.54
US$133.87
+9.25%
7.76%US$162.00US$120.00US$90.1118
US$126.12
Fair Value
15.6% overvalued intrinsic discount
17
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/16 22:12
End of Day Share Price 2026/09/16 00:00
Earnings2026/07/05
Annual Earnings2025/12/28

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Revvity, Inc. is covered by 40 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Robert BambergerBaird
Luke SergottBarclays